Note: Descriptions are shown in the official language in which they were submitted.
CA 02503871 2012-05-17
1
An Immunogenic Composition for Generating an
Immune Response Against Polio Virus
The present invention relates to immunogenic compositions comprising a dried
solid
or high viscosity liquid formulation of inactivated polio virus (IPV) which
retains
immunogenicity. The invention also includes a vaccine comprising a dried solid
or
high viscosity liquid formulation of IPV. A further aspect of the invention is
a
process for preserving inactivated polio virus (IPV) as a dried solid or high
viscosity
liquid. This process comprises preparing a sample by suspending or dissolving
IPV
and a bacterial polysaccharide in a solution of a stabilising agent and
subjecting the
sample to temperature and pressure conditions which result in solvent being
lost from
the sample. Pressure and temperature conditions are maintained or adjusted so
that
solvent is removed and the sample dries to form a solid or high viscosity
liquid. Such
formulations may be reconstituted prior to use or used directly.
IPV is well known as a component of vaccines, however, it is formulated as a
liquid,
for example in Infanrix penta S. The process of freeze-drying IPV has been
associated with the loss of antigenicity so that it is difficult to formulate
an effective
vaccine comprising a dried form of IPV. Dried vaccine formulations are known,
particularly in the case of bacterial polysaccharides. The PRP polysaccharide
of
Haemophilus influenzae b (Hib) is frequently formulated as a dried solid, for
example
in Infanrix hexa (W099/48525).
There are several reasons why a dried formulation of IPV would be
advantageous.
Dried formulations have good storage properties and can increase the shelf
life of a
vaccine containing IPV. The possibility of drying IPV also makes IPV a more
flexible
vaccine constituent and enables it to be formulated in new combination
vaccines
which were not previously possible. Some vaccines contain liquid and dried
solid
components which are mixed just prior to administration (for example Infanrix
hexa ). Infanrix Hexa contains a dried Hib component which is reconstituted
with
DTPa-HepB-IPV just prior to use. By formulating IPV together with Hib as a
dried
solid, it would be possible to add further components to the liquid part of
the vaccine,
which might otherwise be incompatible with IPV.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
2
Several techniques for drying vaccine components are known in the art.
Traditionally,
this has been accomplished using the process of freeze drying in which a
solution of
the substance is made and the sample is frozen. During the primary drying
phase,
most of the water is removed by sublimation from ice under reduced pressure
conditions and a porous `cake' is formed. This is usually followed by a
secondary
drying phase when the pressure and temperature are changed and water is
evaporated
from the solid 'cake'. The resulting lyophilised sample has improved stability
compared to a liquid formulation. However, the freeze drying process is
lengthy and
can be the rate limiting step in a production process.
Product variability is also a problem when many samples are being batch
lyophilised
in a large dryer unit. The conditions on the shelves of the freeze dryer vary
between
different positions leading to samples lyophilising at different rates under
different
conditions. For certain biological materials such as live virus, there can be
significant
loss of activity during the freeze drying process (Pikal (1994) ACS Symposium
567:
120-133). Many freeze dried substances are still unstable at ambient
temperature
(Carpenter et al (1994) ACS Symposium 567; 134-147).
Damage caused by the process of freezing may be circumvented to some degree by
the use of cryoprotectants such as polyols. Further improvements on the
process of
lyophilisation have also been made by avoiding freezing the sample during the
process and removing water by boiling (W096/40077; US6306345). This method
involves preparing a mixture of a glass-matrix forming material in a suitable
solvent
together with the sample to be preserved, evaporating bulk solvent from the
mixture
to obtain a syrup, exposing the syrup to a pressure and temperature sufficient
to cause
boiling of the syrup and removing residual solvent.
A similar method was described in US5,766,520, in which the process involves
partially removing the water to form a viscous fluid and further subjecting
the syrup
to vacuum to cause it to `boil' and further drying at temperatures
substantially lower
than 100 C. This method still suffers from some of the problems of
conventional
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
3
freeze-drying. When the process is carried out in a large freeze-dryer,
samples will
dry at different rates depending on their position on the shelf and this leads
to
different samples loosing different amount of activity during the drying
process. This
leads to a lack of consistency within a batch.
To date, no successful example of making a dried solid vaccine formulation of
IPV
that retains a high degree of antigenicity and/or immunogenicity has been
reported.
Accordingly, the present invention discloses an immunogenic composition
comprising IPV and a stabilising agent, formulated as a dried composition or
highly
viscous liquid, which after reconstitution is capable of generating an immune
response
against polio virus. The presence of a stabilising agent is crucial to the
preservation of
antigens and polyols are shown to be effective. IPV is preferably dried in the
presence
of a bacterial polysaccharide which leads to retention of a higher percentage
of the
original antigens in terms of antigenicity and/or immunogenicity. The present
invention encompasses methods of preserving a composition comprising IPV,
preferably in the presence of a polyol and a bacterial polysaccharide, wherein
the
antigenicity and/or immunogenicity of IPV is retained. Lyophilisation of IPV
in the
presence of polysaccharides leads to an improvement in antigen retention for
IPV
compared to lyophilisation of IPV alone. In addition, the immunogenicity of
Hib is
also enhanced by being formulated together with IPV as a dried solid or highly
viscous liquid. In particular, when reconstituted extemporaneously with liquid
DTP
vaccines (described below), the inventors have found that Hib titres are not
as reduced
by the aluminium hydroxide component of the DTP vaccine as would have been the
case without the presence of IPV.
The method of drying used can also influence the antigenicity and/or
immunogenicity
retention of IPV. A foam drying process for drying IPV was more effective at
retaining antigenicity of IPV than conventional freeze drying techniques.
Surprisingly, the inclusion of a freezing step in the foam drying process did
not lead
to loss of antigenicity but rather led to the development of a quick and
effective
preservation process. A further preferred method of the invention retains high
levels
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
4
of IPV antigenicity and/or immunogenicity by drying the sample containing IPV
without freezing or foam formation, resulting in the formation of a dried
formulation,
preferably a highly viscous liquid formulation.
The invention provides a dried formulation of IPV which will have benefits of
storage
stability. The dried formulation can be reconstituted quickly and easily just
prior to
administration. Where the preferred foam drying process is used, the foamed
cake is
particularly easily reconstituted due to the greater surface area of the cake.
Additional benefits of a dried solid or highly viscous liquid formulation of
IPV and
Hib include enhanced immunogenicity of the Hib component. It is well known
that in
multi-component vaccines, other parts of the vaccine formulation can lead to
interference with Hib immunogenicity (W096/40242, W097/00697). The inclusion
of IPV in a dried formulation with Hib can reduce this problem, especially if
the dried
IPV-Hib composition is mixed with diphtheria, tetanus and pertussis components
prior to administration.
Although lyophilisation of IPV in the presence of a bacterial polysaccharide
is
possible using a conventional freeze drying approach, it is preferred to use a
foam
drying technique or a gentle drying process which does not involve freezing or
foam
formation. These processes result in even greater antigenicity and/or
immunogenicity
retention in IPV and the resultant cake is also easier and quicker to
reconstitute. The
processes also have advantages in being quicker and more energy efficient than
standard freeze-drying techniques. Since the lyophilisation step is often the
rate
limiting step in vaccine production, the use of the preferred processes would
result in
higher levels of vaccine production without additional investment in plant.
The
introduction of a freezing step into the preferred foam drying process also
leads to
improved batch reproducibility.
Description of figures
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
Figure 1 - Photographs of vials containing the preservation sample at
different stages
of the foam drying process.
A - Shows the appearance of the preservation samples as inserted into the
freeze
drying as a liquid formulation.
5 B - Shows the appearance of the preservation samples as the pressure is
reduced to
1.51nbars. The samples begin to freeze at slightly different rates due to
differing
conditions in each vial.
C - Shows the appearance of the preservation samples at 0.1mbars, where all
samples have become completely frozen.
D - Shows the appearance of the preservation samples as the pressure is
increased to
0.8 - 3.5mbars. A foamed glass is formed as the preservation sample foams and
solvent evaporates.
Figure 2- Photograph of the highly viscous liquid in inverted vials.
Detailed description
Immunogenic compositions of the invention
The invention includes immunogenic compositions, formulated as a dried solid
or a
highly viscous liquid comprising IPV and a stabilising agent, in which the
antigenicity
and/or immunogenicity of IPV is retained following reconstitution. The dried
solid or
highly viscous liquid formulation of IPV is capable of generating an immune
response, preferably a protective immune response, against polio virus,
preferably
after reconstitution and inoculation.
IPV is defined as inactivated polio virus (preferably comprising types 1, 2
and 3 as is
standard in the vaccine art, most preferably the Salk polio vaccine). A
vaccine dose
of IPV contains 20-80, preferably 40 or 80 D-antigen units of type 1
(Mahoney), 4-
16, preferably 8 or 16 D-antigen units of type 2 (MEF-1) and 20-64, preferably
32 or
64 D-antigen units of type 3 (Saukett).
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
6
When dried by a method of the invention, preferably the antigenicity of 1, 2,
or all 3
of types 1, 2 and 3 of polio virus are retained; more preferably the
antigenicity of type
1; type 2; type 3; type 1 and type 2; type 1 and type 3; type 2 and type 3 ;or
type 1,
type 2 and type 3 is retained at a level of at least 40%, 50%, 60%, 70%, 80%,
90%,
95% or 98% of the antigenicity of a reference sample which has not been
subjected to
the drying process. This can be measured, following reconstitution of the
dried solid
or highly viscous liquid in an aqueous solution, by any suitable method
including by
ELISA using polyclonal and/or monoclonal antibodies against polio virus type
1, 2
and/or 3.
When dried by a method of the invention, preferably the immunogenicity of 1,
2, or
all 3 of types 1, 2 and 3 of polio virus are retained; more preferably the
immunogenicity of type 1; type 2; type 3; type 1 and type 2; type 1 and type
3; type 2
and type 3 ; or type 1, type 2 and type 3 is retained at a level of at least
40%, 50%,
60%, 70%, 80%, 90%, 95% or 98% of the immunogencity of a reference sample
which has not been subjected to the drying process. This can be measured,
following
reconstitution of the dried solid or highly viscous liquid in an aqueous
solution, by
any suitable method. In a preferred method, the dried formulation is
reconstituted in
an aqueous solution and is inoculated into an animal, preferably a rat. After
a suitable
period of time, antisera are collected from the inoculated animals and
seroconversion
is tested. Preferably, a relative potency of at least 0.4, 0.5, 0.6, 0.7, 0.8
or 0.9 is
achieved, compared to an undried reference sample.
A dried solid composition is a formulation which has had solvent removed by a
process of lyophilisation, sublimation, evaporation or desiccation so that
less than or
equal to 15%, 12%, 10%, 7%, 5%, 4%, preferably 3%, 2% or most preferably 1% .
solvent remains. The term `dried solid' comprises glasses, rubbers or
crystalline solids
with a solid appearance. Any of the methods described above can be used to
make
such a dried solid. Solvent is removed by sublimation, boiling or evaporation,
preferably by evaporation.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
7
A highly viscous liquid is defined as a material with a solvent content less
than or
equal to 15, 12, 10, preferably 8, 5, 4, 3, 2 or 1 %. The highly viscous
liquid has a
sufficiently low solvent content such that the active agent is preserved in a
stable state
for at least 3,6, 9,12 or 24 months at 4 C, allowing the active agent to
retain at least
40, 50, 60, preferably 70, 80, 90, 95% of its antigenicity and/or
immunogencity over
this period. The highly viscous liquid has not been exposed to the formations
of
bubbles that is involved in foam formation. Preferably, the highly viscous
liquid has a
solid appearance but is a glass and is able to flow very slowly over a period
of days,
preferably weeks, more preferably months.
Immunogenic compositions of the invention are formulated as a dried solid or
highly
viscous liquid comprising IPV and a stabilising agent and preferably a
bacterial
polysaccharide. The stabilising agent is any of the compositions described
below. The
bacterial polysaccharide comprises capsular polysaccharides derived from any
bacterium, preferably one or more of Neisseria meningitidis, Haemophilus
influenzae
b, Streptococcus pneumoniae, Group A Streptococci, Group B Streptococci,
Staphylococcus aureus or Staphylococcus epidermidis.
Preferably the PRP capsular polysaccharide of Haemophilus influenzae b is
present as
a dried solid or highly viscous liquid. In a further preferred embodiment, the
immunogenic composition comprises dried solid or highly viscous liquid
formulations
of capsular polysaccharides derived from one or more of serogroups A, C, W-135
and Y of Neisseria meningitidis (meningococcal polysaccharides). A further
preferred
embodiment comprises dried solid or highly viscous liquid formulations of
capsular
polysaccharides derived from Streptococcus pneuinoniae. The pneumococcal
capsular
polysaccharide antigens are preferably selected from serotypes 1, 2, 3, 4, 5,
6B, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F (most
preferably from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F). A
further
preferred embodiment contains the Type 5, Type 8 or 336 capsular
polysaccharides of
Staphylococcus aureus. A further preferred embodiment contains the Type I,
Type II
or Type III capsular polysaccharides of Staphylococcus epidermidis. A further
preferred embodiment contains the Type Ia, Type Ic, Type II or Type III
capsular
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
8
polysaccharides of Group B streptocoocus. A further preferred embodiment
contains
the capsular polysaccharides of Group A streptococcus, preferably further
comprising
at least one M protein and more preferably multiple types of M protein.
In one embodiment of the invention, the bacterial polysaccharides are full
length,
being purified native polysaccharides. In an alternative embodiment of the
invention,
the polysaccharides are sized between 2 and 20 times, preferably 2-5 times, 5-
10
times, 10-15 times or 15-20 times, so that the polysaccharides are smaller in
size for
greater manageability. Oligosaccharides are used in a preferred embodiment.
Oligosaccharides typically contain between 2 and 20 repeat units.
The invention further includes immunogenic compositions comprising more than
one
bacterial polysaccharide and IPV as a dried solid or highly viscous liquid.
Preferably,
IPV is combined with one or more of Hib (Haemophilus influenzae type b) PRP
polysaccharide and/or meningococcal A, C, W and/or Y polysaccharides and/or
pneumococcal polysaccharides. Most preferably the active agents comprise, IPV
and
Hib; IPV and MenC; IPV and Hib and MenC; IPV and MenA and C; IPV and Hib
and Men A and C; IPV and Hib and Men A and C and Y; or IPV and Hib and Men C
and Y.
The above particularised active agents may also comprise one or more
pneumococcal
capsular polysaccharides as described below.
In the above compositions where polysaccharides are used, oligosaccharides may
also
be employed (as defined above).
Although these compositions may be adjuvanted (as described below), they are
preferably unadjuvanted or preferably do not comprise aluminium salts.
Preferably the polysaccharides or oligosaccharides are conjugated to a peptide
or
carrier protein comprising T-helper epitopes (as described below).
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
9
Capsular polysaccharides present in immunogenic compositions of the invention
are
unconjugated or conjugated to a carrier protein such as tetanus toxoid,
tetanus toxoid
fragment C, diphtheria toxoid, CRM197, pneumolysin, Protein D (US6342224).
Tetanus toxin, diphtheria toxin and pneumolysin are detoxified either by
genetic
mutation and/or preferably by chemical treatment. A preferred embodiment of
the
invention has Hib conjugated to tetanus toxoid.
Where more than one conjugated polysaccharide is present in the immunogenic
composition of the invention, the polysaccharides are conjugated to the same
carrier
protein or to different carrier proteins. Preferred embodiments of the
invention contain
meningococcal polysaccharides conjugated to a carrier protein. Where
conjugated
Hib and meningococcal polysaccharides are present, they are conjugated to the
same
carrier protein or to different carrier proteins.
The polysaccharide conjugate may be prepared by any known coupling technique.
In
a preferred coupling technique, the polysaccharide is coupled via a thioether
linkage.
This conjugation method relies on activation of the polysaccharide with 1-
cyano-4-
dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The
activated polysaccharide may thus be coupled directly or via a spacer group to
an
amino group on the carrier protein. Preferably, the cyanate ester is coupled
with
hexane diamine and the amino-derivatised polysaccharide is conjugated to the
carrier
protein using heteroligation chemistry involving the formation of the
thioether
linkage. Such conjugates are described in PCT published application W093/15760
Uniformed Services University.
The conjugates can also be prepared by direct reductive amination methods as
described in US 4365170 (Jennings) and US 4673574 (Anderson). Other methods
are
described in EP-0-161-188, EP-208375 and EP-0-477508.
A further method involves the coupling of a cyanogen bromide activated
polysaccharide derivatised with adipic acid hydrazide (ADH) to the protein
carrier by
Carbodiimide condensation (Chu C. et al Infect. Immunity, 1983 245 256).
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
Polysaccharides which are incorporated as part of the immunogenic composition
of
the invention may be unabsorbed or absorbed onto an adjuvant, preferably an
aluminium salt (aluminium phosphate or aluminium hydroxide), most preferably
5 aluminium phosphate.
Immunogenic compositions of the invention comprise a stabilising agent which
can
help to prevent damage during the desiccation process. Any of the stabilising
agent
described below, including glass forming polyols can be incorporated into the
10 immunogenic composition, whether as a dried solid, a foamed glass or a
highly
viscous liquid composition using the processes of the invention. Preferred
stabilising
agents include sucrose, sorbitol, lactose and trehalose.
The preferred combinations, dried by the processes of the invention may be
combined
with other antigens in a combination vaccine which are desiccated or liquid
formulations which are used to reconstitute the dried components.
Additional components
Dried solid or highly viscous liquid formulations of the invention
incorporating IPV
and a stabilising agent may additionally be formulated with further vaccine
components. A preferred vaccine contains a dried solid or highly viscous
liquid
formulation of IPV and a bacterial polysaccharide which may be mixed with a
liquid
formulation comprising additional vaccine components. After reconstitution of
the
solid components with the liquid components, the complete vaccine is
administered
by injection.
The additional components include capsular polysaccharides derived from one or
more of Neisseria meningitidis, Streptococcus pneumoniae, Group A
Streptococci,
Group B Streptococci, Staphylococcus aureus or Staphylococcus epidermidis. In
a
preferred embodiment, the immunogenic composition comprises capsular
polysaccharides derived from one or more of serogroups A, C, W-135 and Y of
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
11
Neisseria meningitidis. A further preferred embodiment comprises capsular
polysaccharides derived from Streptococcus pneumoniae. The pneumococcal
capsular
polysaccharide antigens are preferably selected from serotypes 1, 2, 3, 4, 5,
6B, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F (most
preferably from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).. A
further
preferred embodiment contains the Type 5, Type 8 or 336 capsular
polysaccharides of
Staphylococcus aureus. A further preferred embodiment contains the Type I,
Type II
or Type III capsular polysaccharides of Staphylococcus epidermidis. A further
preferred embodiment contains the Type Ia, Type Ic, Type II or Type III
capsular
polysaccharides of Group B streptocoocus. A further preferred embodiment would
contain the capsular polysaccharides of Group A streptococcus, preferably
further
comprising at least one M protein and more preferably multiple types of M
protein.
The immunogenic composition of the invention may be formulated with protein
antigens. Preferred pneumococcal proteins antigens are those pneumococcal
proteins
which are exposed on the outer surface of the pneumococcus (capable of being
recognised by a host's immune system during at least part of the life cycle of
the
pneumococcus), or are proteins which are secreted or released by the
pneumococcus.
Most preferably, the protein is a toxin, adhesin, 2-component signal
tranducer, or
lipoprotein of Streptococcus pneumoniae, or fragments thereof. Particularly
preferred
proteins include, but are not limited to: pneumolysin (preferably detoxified
by
chemical treatment or mutation) [Mitchell et al. Nucleic Acids Res. 1990 Jul
11;
18(13): 4010 "Comparison of pneumolysin genes and proteins from Streptococcus
pneunoniae types 1 and 2.", Mitchell et al. Biochim Biophys Acta 1989 Jan 23;
1007(1): 67-72 "Expression of the pneumolysin gene in Escherichia coli: rapid
purification and biological properties.", WO 96/05859 (A. Cyanamid), WO
90/06951
(Paton et al), WO 99/03884 (NAVA)]; PspA and transmembrane deletion variants
thereof (US 5804193 - Briles et al.); PspC and transmembrane deletion variants
thereof (WO 97/09994 - Briles et al); PsaA and transmembrane deletion variants
thereof (Berry & Paton, Infect Immun 1996 Dec;64(12):5255-62 "Sequence
heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for
virulence of
Streptococcus pneumoniae"); pneumococcal choline binding proteins and
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
12
transmembrane deletion variants thereof; CbpA and transmembrane deletion
variants
thereof (WO 97/41151; WO 99/51266); Glyceraldehyde-3-phosphate -
dehydrogenase (Infect. Immun. 1996 64:3544); HSP70 (WO 96/40928); PcpA
(Sanchez-Beato et al. FEMS Microbiol Lett 1998, 164:207-14); M like protein,
(EP
0837130) and adhesin 18627, (EP 0834568). Further preferred pneumococcal
protein
antigens are those disclosed in WO 98/18931, particularly those selected in WO
98/18930 and PCT/US99/30390.
Preferred Neisserial proteins to be formulated with the immunogenic
composition of
the invention include TbpA (W093/06861; EP586266; W092/03467; US5912336),
TbpB (W093/06861; EP586266), Hsf (W099/31132), NspA (W096/29412), Hap
(PCT/EP99/02766), PorA, PorB, OMP85 (also known as D15) (W000/23595), Pi1Q
(PCT/EP99/03603), P1dA (PCT/EP99/06718), FrpB (W096/31618 see SEQ ID
NO:38), FrpA or FrpC or a conserved portion in commen to both of at least 30,
50,
100, 500, 750 amino acids (W092/01460), LbpA and/or LbpB (PCT/EP98/05117;
Schryvers et al Med. Microbiol. 1999 32: 1117), FhaB (W098/02547), HasR
(PCT/EP99/05989), lipo02 (PCT/EP99/08315), M1tA (W099/57280) and ctrA
(PCT/EPOO/00135). Neisserial protein may be added as purified proteins or as
part of
an outer membrane vesicle preparation.
The immunogenic composition is preferably formulated with antigens providing
protection against one or more of Diphtheria, tetanus and Bordetella pertussis
infections. The pertussis component may be killed whole cell B. pertussis (Pw)
or is
preferably acellular pertussis (Pa) which contains at least one antigen
(preferably two
or all three) from PT, FHA and 69kDa pertactin certain other acellular
vaccines also
contain agglutinogens , such as Fim 2 and Fim 3 and these vaccines are also
contemplated for use in the invention. Typically, the antigens providing
protection
against Diphtheria and Tetanus are Diphtheria toxoid and tetanus toxoid. The
toxoids
are chemically inactivated toxins, for example following treatment with
formaldehyde, or toxins inactivated by the introduction of one or more point
mutations.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
13
Alternatively the immunogenic composition of the invention may be provided as
a kit
with the dried solid, foamed glass or highly viscous liquid in one container
and liquid
DTPa or DTPw in another container. Such kits can for example, comprise a dual
chamber syringe with the dried and liquid components contained in the same
syringe
but in different chambers. The dried component is then reconstituted with the
liquid
vaccine immediately prior to injection as a single vaccine. Thus for example,
the dried
solid, foamed glass or highly viscous liquid of the invention is reconstituted
with the
liquid DTPa or DTPw vaccine (preferably extemporaneously) and administered as
a
single vaccine. The DTPa or DTPw vaccine typically is adjuvanted at least in
part
with an aluminium salt, such as aluminium phosphate and/or aluminium hydroxide
(for instance Infanrix and Tritanrix vaccines of GlaxoSmithKline
Biologicals
s.a.).
The immunogenic composition is optionally formulated with one or more antigens
that can protect a host against non-typeable Haenaophilus influenzae, RSV
and/or one
or more antigens that can protect a host against influenza virus. Preferred
non-
typeable H. influenzae protein antigens include Fimbrin protein (US 5766608)
and
fusions comprising peptides therefrom (eg LB1 Fusion) (US 5843464 - Ohio State
Research Foundation), OMP26, P6, protein D, TbpA, TbpB, Hia, Hmwl, Hmw2,
Hap, and D15.
Preferred influenza virus antigens include whole, live or inactivated virus,
split
influenza virus, grown in eggs or MDCK cells, or Vero cells or whole flu
virosoines
(as described by R. Gluck, Vaccine, 1992, 10, 915-920) or purified or
recombinant
proteins thereof, such as HA, NP, NA, or M proteins, or combinations thereof.
Preferred RSV (Respiratory Syncytial Virus) antigens include the F
glycoprotein, the
G glycoprotein, the HN protein, the M protein or derivatives thereof.
Combination vaccines comprising DTP-Hib are known in the art. However there
are
problems associated with certain formulations which involve simple mixing of
Hib
with other antigens. Unless carefully formulation, the antibody titres raised
against the
CA 02503871 2011-06-29
WO 2004/039399 PCT/EP2003/012160
14
Hib component can be lower than those elicited by the same dose of Hib
inoculated
separately, due to interference with other components of the vaccine. Although
this
problem is well known in the art and has been addressed in various ways, the
immunogenic compositions of the invention in which Hib and 1PV are formulated
together as a dried solid or highly viscous liquid provides an alternative
solution to
this problem.
The immunogenic compositions of the invention may form part of a vaccine kit
in
which IPV and Hib are present in one component of the kit and further
components,
as described above, are present in a second component, for example, a dual
chamber
syringe as described herein. The two components are mixed together just before
administration of the vaccine. In such formulations, the component comprising
IPV
and Hib is preferably a dried solid, foamed glass or highly viscous liquid,
although it
is optionally formulated as a liquid. This formulation results in antibody
titres against
the Hib component being clinically acceptable to provide protection against
the
Haemophilus influenzae b pathogen. Typically, the antibody titre in the
combination
vaccine are at least 85%, 90%, preferably about 100% or more of those elicited
by the
same dose of Hib in a monovalent Hib vaccine.
Vaccines of the invention
The immunogenic compositions of the invention described above are preferably
formulated as a vaccine. Preferably, the vaccine contains an amount of an
adjuvant
sufficient to enhance the immune response to the immunogen. Suitable adjuvants
include, but are not limited to, aluminium salts such as aluminium hydroxide
and
aluminium phosphate, squalene mixtures (SAF-1), muramyl peptide, saponin
derivatives, mycobacterium cell wall preparations, monophosphoryl lipid A,
mycolic
acid derivatives, non-ionic block copolymer surfactants, Quil A. cholera toxin
B
subunit, polphosphazene and derivatives, and immunostimulating complexes
(ISCOMs) such as those described by Takahashi et al. (1990) Nature 344:873-
875.
For veterinary use and for production of antibodies in animals, mitogenic
components
of Freund's adjuvant can be used.
*Trade-mark
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
The vaccine formulations of the invention are preferably reconstituted prior
to use.
Reconstitution involves the mixing of a liquid component of the vaccine with
the
dried solid, foamed glass or highly viscous liquid formulation of the
invention. The
5 invention also encompasses a container with a water repellent internal
surface
containing the immunogenic composition or vaccine of the invention. The use of
such
a container is advantageous because it leads to the dried composition sitting
at the
bottom of the tube in a form in which it is more easy to reconstitute.
10 It is advantageous to incorporate a coloured dye into the preservation
sample in order
to allow easier visualisation of the dried composition of the invention. This
is
particularly important during reconstitution to ensure that the dried solid or
highly
viscous liquid is thoroughly reconstituted prior to use. Preferably, the
coloured dye
maintains its colour at a neutral pH and is compatible with injection into a
patient.
15 Most preferably the coloured dye is phenol red.
As with all immunogenic compositions or vaccines, the immunologically
effective
amounts of the immunogens must be determined empirically. Factors to be
considered include the immunogenicity, whether or not the immunogen will be
complexed with or covalently attached to an adjuvant or carrier protein or
other
carrier, route of adminstrations and the number of immunising dosages to be
adminstered. Such factors are known in the vaccine art and it is well within
the skill
of immunologists to make such determinations without undue experimentation.
The substance can be present in varying concentrations in the immunogenic
composition of the invention. Typically, the minimum concentration of the
substance
is an amount necessary to achieve its intended use, while the maximum
concentration
is the maximum amount that will remain in solution or homogeneously suspended
within the initial mixture. For instance, the minimum amount of a therapeutic
agent is
preferably one which will provide a single therapeutically effective dosage.
Super-
saturated solutions can also be used if a foamed glass is formed prior to
crystallisation. For bioactive substances, the minimum concentration is an
amount
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
16
necessary for bioactivity upon reconstitution and the maximum concentration is
at the
point at which a homogeneous suspension cannot be maintained. In the case of
single-dosed units, the amount is that of a single therapeutic application
Generally, it
is expected that each dose will comprise 1-100ug of protein antigen,
preferably 5-
50ug and most preferably 5-25ug. Preferred doses of bacterial polysaccharides
are 10-
20ug, 10-5ug, 5-2.5ug or 2.5-lug. The preferred amount of the substance varies
from
substance to substance but is easily determinable by one of skill in the art.
Methods of the invention
The methods of the invention are for preserving a composition comprising IPV
and a
stabilising agent, resulting in a composition in which the antigenicity of IPV
is
retained. Preferably, a bacterial polysaccharide is incorporated in the sample
to be
dried.
In one embodiment, the method of the invention involves drying IPV and
comprises
the steps of-
= preparing a preservation sample by suspending or dissolving IPV in a
solution of a
stabilising agent; preferably a bacterial polysaccharide and/or a glass
forming
polyol are present in the preservation sample;
= subjecting the preservation sample to such temperature and pressure
conditions
that solvent is lost from the preservation sample ; and
= removing solvent until the preservation sample dries to form a solid or
highly
viscous liquid in which the antigenicity and/or immunogenicity of IPV is
retained.
In a preferred embodiment, the preservation sample is inserted into a
container with a
water repellent interior prior to drying.
A further method of the invention involves foam drying, comprising the steps
of:
= preparing a preservation sample by suspending or dissolving IPV in a
solution of a
stabilising agent; preferably a bacterial polysaccharide and/or a glass
forming
polyol are present in the preservation sample;
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
17
= subjecting the preservation sample to such temperature and pressure
conditions
that the preservation sample forms a foam; and
= removing solvent until the foam dries to form a solid in which the
antigenicity
and/or immunogenicity of IPV is retained.
A preferred foam drying method of the invention uses a container with a water
repellent interior surface and contains the steps of-
= preparing a preservation sample by suspending or dissolving IPV and
preferably a
bacterial polysaccharide in a solution of a stabilising agent;
= inserting the preservation sample into a container with a water repellent
interior
surface;
= subjecting the container containing the preservation sample to such
temperature
and pressure conditions so that the preservation sample forms a foam;
= removing solvent until the foam dries to form a solid in which the
antigenicity
and/or immunogenicity of IPV is retained.
The foam drying methods of the invention described above optionally comprise a
freezing step. The preservation sample may be wholly or partially frozen.
Therefore
some methods of the invention comprise the steps of:
= preparing an at least partially frozen preservation sample by suspending or
dissolving IPV and preferably a bacterial polysaccharide in a solution of a
stabilising agent and freezing the mixture;
= subjecting the at least partially frozen preservation sample to such
temperature
and pressure conditions that the preservation sample forms a foam; and
= removing solvent until the foam dries to form a solid in which the
antigenicity
and/or immunogenicity of IPV is retained.
The freezing step of the above method is preferably by the process of quench
freezing
in which reduction of pressure is the cause of freezing by evaporation. This
causes
rapid freezing of the sample which leads to less antigen loss. Therefore a
process of
the invention includes the steps of:
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
18
= preparing a preservation sample by suspending or dissolving IPV and
preferably a
bacterial polysaccharide in a solution of a stabilising agent;
= subjecting the preservation sample to reduced pressure such that the
preservation
sample becomes at least partially frozen;
= subjecting the at least partially frozen preservation sample to such
temperature
and pressure conditions that the preservation sample forms a foam; and
= removing solvent until the foam dries to form a solid in which the
antigenicity
and/or immunogenicity of IPV is retained.
A further preferred method of the invention is used for preserving IPV and
comprises
the steps of-
= preparing a preservation sample by suspending or dissolving IPV in a
solution of a
stabilising agent;
= subjecting the preservation sample to such temperature and pressure
conditions
that the preservation sample looses solvent by evaporation, without bubbling
to
form a foam and preferably without freezing;
= removing solvent until the sample dries to form a highly viscous liquid in
which
and antigencity and/or immunogenicity of IPV is retained.
The methods of the invention produce a formulation of IPV that is able to
withstand
extended storage during which the antigenicity and/or immunogenicity of IPV is
maintained. Preferably the IPV retains at least 40, 50, 60, 70, preferably 80,
90, 95%
of its original antigenicity and/or immunogenicity over a period of at least
3, 6, 9, 12,
24 months storage at 4 C. Antigenicity and immunogenicity are measured after
reconstitution of IPV in a suitable aqueous solution, and using a suitable
method, for
instance those described above.
The method of drying without freezing or foam formation is particularly
applicable
for use where the active agents to be dried are prone to loss of activity
and/or
antigenicity during the drying process due to exposure to freezing or the
bubbling
associated with foam formation. It is also particularly applicable for use
where a
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
19
lower concentration of the glass forming polyol is advantageous and/or where a
shorter drying process is preferred.
Stabilising agent
The stabilising agent to be used in the methods of the invention will
preferably
comprise glass forming polyols. Suitable materials include, but are not
limited to, all
polyols, including carbohydrate and non-carbohydrate polyols. Preferably the
stabilising polyol enables the active agent to be stored without substantial
loss of
activity by denaturation, aggregation or other means. Particularly suitable
materials
include sugars, sugar alcohols and carbohydrate derivatives. Preferably, the
glass
forming polyol is a carbohydrate or derivatives thereof, including glucose,
maltulose,
iso-maltulose, lactulose, sucrose, maltose, lactose, iso-maltose, maltitol,
lactitol,
palatinit, trehalose, raffinose, stachyose, melezitose or dextran, most
preferably
trehalose, sucrose, sorbitol, raffinose, mannitol, lactose, lactitol or
palatinit.
Bacterial polysaccharides act as a stabilising agent and preferred embodiments
of the
invention incorporate bacterial polysaccharides as a constitutent of the
stabilising
agent. The bacterial polysaccharide plays a dual role of stabilising agent and
immunogen in this embodiment.
Carbohydrates include, but are not limited to, monosaccharides, disaccharides,
trisaccharides, oligosaccharides and their corresponding sugar alcohols,
polyhydroxyl
compounds such as carbohydrate derivatives and chemically modified
carbohydrates,
hydroxyethyl starch and sugar copolymers. Both natural and synthetic
carbohydrates
are suitable for use. Synthetic carbohydrates include, but are not limited to,
those
which have the glycosidic bond replaced by a thiol or carbon bond. Both D and
L
forms of the carbohydrates may be used. The carbohydrate may be non-reducing
or
reducing. Where a reducing carbohydrate is used, the addition of inhibitors of
the
Maillard reaction is preferred.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
Reducing carbohydrates suitable for use in the invention are those known in
the art
and include, but are not limited to, glucose, maltose, lactose, fructose,
galactoase,
mannose, maltulose and lactulose. Non-reducing carbohydrates include, but are
not
limited to, non-reducing glycosides of polyhydroxyl compounds selected from
sugar
5 alcohols and other straight chain polyalcohols. Other useful carbohydrates
include
raffinose, stachyose, melezitose, dextran, sucrose, cellibiose, mannobiose and
sugar
alcohols. The sugar alcohol glycosides are preferably monoglycosides, in
particular
the compounds obtained by reduction of disaccharides such as lactose, maltose,
lactulose and maltulose.
Particularly preferred carbohydrates are trehalose, sucrose, sorbitol,
maltitol, lactitol,
palatinit and glucopyranosyl-l-6-mannitol.
Amino acids can act as stabilising agents and can be used by themselves and
preferably in combination with a polyol. Preferred amino acids include
glycine,
alanine, arginine, lysine and glutamine although any amino acid, or a
combination of
amino acids, peptide, hydrolysed proteins or protein such as serum albumin can
act as
a stabilising agent.
Preferably, the preservation sample will contain a component capable of
inhibiting
crystal formation in the dried solid or highly viscous liquid of the
invention. Salts and
other molecules including amino acids and phenol red inhibit crystal
formation.
The concentration of the stabilising agent used in the process of the
invention may be
between 1% and 50% weight/volume, preferably 1-5%, 5-10%, 5-10%, 15-20%, 20-
25% or 25-50%, most preferably less than 25% (w/v). The amounts of stabilising
agent required is proportional to the amount of salts present. Therefore,
although
levels of stabilising agent between 3% and 10% are preferred, higher
concentrations
of 10% to 25% (w/v) may be required to dry samples with a high salt content.
Container
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
21
Different mixtures and various container shapes and sizes can be processed
simultaneously. Ideally, the container size used is sufficient to contain the
initial
mixture and accommodate the volume of the dried formulation formed thereof.
Typically, this is determined by the mass of the glass forming material, the
surface
area of the container and the temperature and pressure conditions, which
determine
whether foaming occurs. The mass of glass forming material must be sufficient
to
give viscous syrup, optionally to be foamed which translates practically as a
minimal
mass per unit area of container surface. This ratio varies from mixture to
mixture and
container used, but is easily determined empirically by one skilled in the art
by
following the procedures set forth herein. Any such containers can be used
including
Wheaton moulded and tube-cut vials.
The processes of the invention preferably use containers with a water
repellent
interior surface. This is achieved through coating the interior surface with a
hydrophobic composition, for instance by siliconisation. Siliconisation is
achieved by
processes that are well known to those skilled in the art. In one method, the
container
is siliconised by rising the interior of the container with an emulsion of
silicone,
followed by processing through an oven at high temperature, typically 350 C.
Alternatively, the water repellent interior surface is achieved by the
container being
made of a water repellent composition.
The water repellent interior surface of the container makes foam formation
more
likely to occur and more reproducible. This allows lower polyol concentrations
to be
used in the preservation sample which in turn decreases the length of time
necessary
to dry the sample, reduces the effect of Maillard reactions or other
interactions with
the polyol harming the active agent. Where the preservation samples comprises
a
vaccine, the resultant foamed glass is reconstituted quickly and easily due to
the lower
amount of polyol present and the resultant vaccine solution is less viscous,
allowing
easier administration. The water repellent interior surface allows easier
reconstitution
of the dried solid or highly viscous liquid since it encourages the sample to
remain as
at the bottom of the container so that it is easier to reconstitute
effectively.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
22
Although singular forms may be used herein, more than one stabilising agent,
more
than one additive, and more than one substance may be present. Effective
amounts of
these components are easily determined by one skilled in the art.
Solvent
The preservation sample is made by dissolving/suspending IPV and a stabilising
agent
in water to make an aqueous solution. Preferably, water is present in the
preservation
sample at a level of 5 to 98% by volume, more preferably 80-98% by volume,
most
preferably 85-98% by volume.
The volume of solvent can vary and will depend upon the stabilising agent and
the
substance to be incorporated as well as any additives. The minimum volume
required is an amount necessary to solubilise the various components. However,
homogeneously dispersed suspensions of the substance(s) can also be used.
Suitable
amounts of the components in specific embodiments are easily determinable by
those
skilled in the art in light of the examples provided herein.
Various additives can be put into the preservation sample. Typically, the
additives
enhance foam formation and /or the drying process and/or contribute to the
solubilization of the substance. Alternatively, the additives contribute to
the stability
of the substance incorporated within the solid. One or more additives may be
present.
As an example, addition of volatile/effervescent salts allows larger initial
volumes and
results in higher surface area within the foamed glass, thus effecting
superior foam
formation and more rapid drying. As used herein, volatile salts are salts
which
volatilise under the conditions used to produce a foamed glass. Examples of
suitable
volatile salts include, but are not limited to, ammonium acetate, ammonium
bicarbonate and ammonium carbonate. Salts that decompose to give gaseous
products
also effect enhanced foam formation and more rapid drying. Examples of such
salts
are sodium bicarbonate and sodium metabisulphite. Preferably, the volatile
salts are
present in an amount of from about 0.01 to 5 M. Concentrations of up to 5 M
are
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
23
suitable for use herein. The resultant foamed glass has uniform foam
conformation
and is significantly drier compared to foamed glass in which
volatile/effervescent
salts are not used.
Another suitable additive is a foam stabilising agent, which can be used in
combination with either the volatile or decomposing salt. This may either be a
surface active component such as an amphipathic molecule (i.e. such as
phospholipids
and surfactants) or an agent to increase the viscosity of the foaming syrup,
such as a
thickening agent such as guar gum and their derivatives.
Another additive is an inhibitor of the Maillard reaction. Preferably, if the
substance
and/or glass matrix-forming material contains carbonyl and amino, imino or
guanidino groups, the compositions further contain at least one
physiologically
acceptable inhibitor of the Maillard reaction in an amount effective to
substantially
prevent condensation of amino groups and reactive carbonyl groups in the
composition. The inhibitor of the Maillard reaction can be any known in the
art. The
inhibitor is present in an amount sufficient to prevent, or substantially
prevent,
condensation of amino groups and reactive carbonyl groups. Typically, the
amino
groups are present on the substance and the carbonyl groups are present on the
glass
matrix forming material, or the converse. However, the amino acids and
carbonyl
groups may be intramolecular within either the substance or the carbohydrate.
Various classes of compounds are known to exhibit an inhibiting effect on the
Maillard reaction and hence to be of use in the compositions described herein.
These
compounds are generally either competitive or non-competitive inhibitors of
the
Maillard reaction. Competitive inhibitors include, but are not limited to,
amino acid
residues (both D and L), combinations of amino acid residues and peptides.
Particularly preferred are lysine, arginine, histidine and tryptophan. Lysine
and
aarginine are the most effective. There are many known non-competitive
inhibitors.
These include, but are not limited to, aminoguanidine and derivatives and
amphotericin B. EP-A-0 433 679 also describes suitable Maillard inhibitors
which
include 4-hydroxy-5, 8-dioxoquinoline derivatives.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
24
Active agents
The methods of the invention are used to preserve inactivated polio virus (IPV
-
preferably comprising types 1, 2 and 3 as is standard in the vaccine art, most
preferably the Salk polio vaccine). IPV contains 20-80, preferably 40 or 8- D-
antigen
units of type 1 (Mahoney), 4-20, preferably 8 or 16 D-antigen units of type 2
(MEF-1)
and 20-64, preferably 32 or 64 D-antigen units of type 3 (Saukett). The IPV
vaccine
formulation is suitable for injection after reconstitution in an aqueous
solution which
preferably contains additional vaccine components.
The bacterial polysaccharide incorporated by the process of the invention are
for
example capsular polysaccharides derived from one or more of Neisseria
meningitidis, Haemophilus influenzae b, Streptococcus pneumoniae, Group A
Streptococci, Group B Streptococci, Staphylococcus aureus or Staphylococcus
epidermidis, preferably the PRP capsular polysaccharides of Haemophilus
influenzae..
Preferred capsular polysaccharides also include those derived from one or more
of
serogroups A, C, W-135 and Y of Neisseria meningitidis. Further preferred
capsular
polysaccharides are derived from Streptococcus pneumoniae. The pneumococcal
capsular polysaccharide antigens are preferably selected from serotypes 1, 2,
3, 4, 5,
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F
and
33F (most preferably from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and
23F). A
further preferred embodiment contains the Type 5, Type 8 or 336 capsular
polysaccharides of Staphylococcus aureus. Further preferred polysaccharides
include
the Type I, Type II or Type III capsular polysaccharides of Staphylococcus
epidermidis, the Type Ia, Type Ic, Type II or Type III capsular
polysaccharides of
Group B streptocoocus. Further preferred polysaccharides include the capsular
polysaccharides of Group A streptococcus, preferably further comprising at
least one
M protein and more preferably multiple types of M protein.
Preferred combinations of active agents to be preserved using the processes of
the
invention comprise IPV. Preferably, IPV is combined with bacterial
polysaccharides
comprising one or more of Hib PRP polysaccharide and/or meningococcal A, C, W
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
and/or Y polysaccharides and/or pneumococcal. polysaccharides. Preferred
combinations include IPV and Hib; IPV and MenC; IPV and MenA and C; IPV and
Hib and Men C or IPV, Hib, Men A and C. Each bacterial polysaccharides may be
present in doses of 1-5 g, 5-10 g, 10-20 g or 20-40 g.
5
Bacterial polysaccharides are unconjugated or conjugated to a carrier protein
such as
tetanus toxoid, tetanus toxoid fragment C, diphtheria toxoid, CRM197,
pneumolysin
or Protein D (US6342224).
10 The polysaccharide conjugate are prepared by any known coupling technique.
A
preferred conjugation method relies on activation of the polysaccharide with 1-
cyano-
4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester.
The
activated polysaccharide is coupled directly or via a spacer group to an amino
group
on the carrier protein. Preferably, the cyanate ester is coupled with hexane
diamine
15 and the amino-derivatised polysaccharide is conjugated to the carrier
protein using
heteroligation chemistry involving the formation of the thioether linkage.
Such
conjugates are described in PCT published application W093/15760 Uniformed
Services University.
20 The conjugates are optionally prepared by direct reductive amination
methods as
described in US 4365170 (Jennings) and US 4673574 (Anderson). Other methods
are
described in EP-0-161-188, EP-208375 and EP-0-477508.
A further method involves the coupling of a cyanogen bromide activated
25 polysaccharide derivatised with adipic acid hydrazide (ADH) to the protein
carrier by
Carbodiimide condensation (Chu C. et al Infect. Immunity, 1983 245 256).
Drying Processes
In one embodiment the process of the invention involves drying IPV in the
presence
of a stabilising agent, preferably in the presence of a bacterial
polysaccharide. In this
process, the preservation sample is subjected to reduced temperature and
pressure
conditions. The temperature is reduced to less than 20 C or 0 C, preferably
less than
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
26
-10 C or -20 C, more preferably -40 C or -60 C. The pressure is reduced to
less
than lmbar, preferably a pressure of, or less than 0.5, 0.1, more preferably
0.05 or
0.01 mbar. The reduced temperature and pressure conditions are maintained for
at
least 10, 12, 16, 20, preferably 24, 36, more preferably 48 or 72 hours.
Solvent is
removed until the preservation sample dries to form a solid.
Throughout this application, solid includes glasses, rubbers and crystals
which form
as the sample dries. Such solids preferably retain a water content of 10-20%
or 5-
10%, preferably 5-6%, 4-5%, or 3-4%, or 2-3%, more preferably 1-2% or 0-1%
(w/w).
Foam drying
A preferred process of the invention involves subjecting the preservation
sample to
such pressure and temperature conditions so that the sample begins to bubble,
forming
a foam.
The temperature within the preservation sample will be different from that
external to
the sample due to the endothermic nature of the evaporation process.
References to
temperature are to the conditions external to the preservation sample, for
instance,
where a large industrial freeze dryer is used, to the temperature of the
shelf. This
usually corresponds to the freeze dryer temperature setting.
A preferred embodiment of the invention achieves this by reducing the pressure
while
maintaining temperature conditions. The pressure is adjusted to at or below 8
, 7, 6,
preferably 5, 4, 3, more preferably 2, 1.5, 1, most preferably 0.8 or 0.5
mbar, while
maintaining the temperature setting at a temperature above 0 C, preferably of
between 10 C to 15 C; 15 C to 20 C; 20 C to 25 C; 25 C to 30 C; or 30
C to
37 C. These conditions are maintained for at least 1, 2, 3, 4, 5, 8, 10, 12,
16 or 24
hours.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
27
Another embodiment of the invention achieves foam formation by changing the
temperature while maintaining reduced the pressure conditions. The temperature
setting is increased to above 20 C, preferably to between 20 C and 30 C; 30
C
and 40 C; 40 C and 50 C; or 50 C and 70 C; or the temperature setting is
in the
range of 10-50 C, preferably 20-40 C, more preferably 25-35 C. Pressure
conditions are maintained at a reduced level of or below 8 , 7, 6, preferably
5, 4, 3,
more preferably 2, 1.5, 1, most preferably 0.8 or 0.5 mbar. These conditions
are
maintained for at least 1, 2, 3, 4, 5, 8, 10, 12, 16 or 24 hours.
Removing solvent to form a foamed glass
A subsequent stage of the foam drying method of the invention involves
removing
solvent until the foam dries to form a solid. In one embodiment of the
invention, this
is achieved by maintaining the pressure and temperature conditions at those
applied
in order to achieve foam formation. For instance, the pressure is maintained
at or
below 8 , 7, 6, preferably 5, 4, 3, more preferably 2, 1.5, 1, most preferably
0.8 or 0.5
mbar while maintaining the temperature setting at a temperature above 0 C,
preferably between 2 C and 10 'C,10 C and 20 C; 20 C and 30 C; 30 C and
35 C, 35 C and 40 C most preferably between 5 C and 25 C. These
temperature
and pressure conditions are maintained for 1, 2, 3, 4, 5, 6, 8, 10, 12, 18
hours or more
in order to obtain a solid with a solvent content less than or equal to 10, 8,
5, 4,
preferably 3, 2 or most preferably 1% (w/w).
Another embodiment of the invention increases the temperature setting during
solvent
removal to a higher temperature setting than that maintained earlier in the
process.
This advantageously allows the solvent to leave the sample at a quicker rate
so that
the method of the invention can be completed in a shorter time. For instance,
the
temperature setting is increased to above 0 C, preferably between 2 C and 10
C ;
10 Cand20 C; 20 C and30 C;30 Cand40 C;40 Cand50 C;50 Cand
60 C while maintaining the pressure at or below 8, 7, 6, preferably 5, 4, 3,
more
preferably 2, 1.5, 1, most preferably 0.8 or 0.5 mbar. These temperature and
pressure
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
28
conditions are maintained for 1, 2, 3, 4, 5, 6, 8, 10, 12, 18 hours or more in
order to
obtain a solid with less than 10, 8, 5, 4, preferably 3, 2 or most preferably
1% (w/w)
water content.
Another embodiment of the invention reduces the pressure setting during
solvent
removal to a lower pressure setting than that used during foam formation. This
advantageously allows the solvent to leave the sample at a quicker rate so
that the
method of the invention can be completed in a shorter time. For instance, the
pressure
setting is decreased to at or below 5,,4, 3, preferably 2, 1, 0.8, more
preferably 0.5,
0.1. most preferably 0.05 or 0.01mbar, while maintaining the temperature at or
above
0 C, preferably between 10 C and 20 C; 20 C and 30 C; 30 C and 35 C or
above 40 C. These temperature and pressure conditions are maintained for 1,
2, 3, 4,
5, 6, 8, 10, 12, 18 hours or more in order to obtain a solid with a solvent
content less
than or equal to 5, 4, preferably 3 or 2 or more preferably 1 % (w/w).
Foam drying including a freezing step
The method of the invention optionally involves freezing the sample. Freezing
the
sample prior to foam drying has the advantage of increased reproducibility
between
samples in a batch. This is due to all the samples starting the process from
the same
physical condition of being frozen. The preservation samples may be wholly or
partially frozen.
Freezing is optionally carried out before subjected the sample to reduced
pressure by
placing the preservation sample at a temperature below 0 C for a suitable
amount of
time to allow the sample to freeze. Preferably the temperature used is at or
below -
10 C, -15 C, -20 C, -30 C, -40 C, -70 C or -140 C. The sample maybe
left at a
temperature below 0 C for 1, 2, 3, 4, 5, 8, 16 or more hours to allow
freezing to
occur.
For some samples, particularly samples that are easily damaged by solvent
crystal
formation such as cell preparations or other biological systems , it is
preferable to
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
29
freeze the sample slowly at a rate of less than or equal to 0.1, 0.5, 1, 2, 3,
4, 5 C per
hour. Other compositions are preserved more effectively by freezing
instantaneously,
for instance by snap freezing in liquid nitrogen. This method is particularly
beneficial
for proteins or viral particles. Freezing by evaporation also results in rapid
freezing of
the sample.
Alternatively, the preservation sample is frozen by subjecting the sample to
reduced
pressure such that the sample becomes wholly or partially frozen. Such quench
freezing is carried out within a bulk freeze dryer apparatus, at a shelf
temperature of
or above 0 C, 10 C, 15 C, 20 C, 30 C, 37 C. Preferably the shelf
temperature is
between 5 and 35 C, more preferably between 10 and 20 C, most preferably at
C. The pressure is optionally reduced initially to 200mbar for 5, 10, 20, 30,
60
minutes or more to allow degassing. In order to freeze the sample, the
pressure is
reduced further to a pressure equal to or below 2, 1, 0.5, 0.2, 0.lmbar. This
pressure is
15 maintained for at least 5, 10, 20 or 30 minutes until the sample is wholly
or partially
frozen.
Subsequent steps of foam formation and removing solvent to form a solid are as
described above.
In a preferred embodiment of the invention, the steps of freezing the sample
within
the freeze dryer and foam formation are performed at a constant temperature,
preferably altering the pressure conditions.
In a further preferred embodiment the steps of freezing the sample within the
freeze
dryer, foam formation and solvent removal to form a solid, are performed at a
constant temperature, preferably altering the pressure conditions.
In a further embodiment of the invention, both pressure and temperature
conditions
are different during the steps of freezing the sample, foam formation and
solvent
removal to form a solid.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
The processes of the invention preferably use containers with a water
repellent
interior surface. This is achieved through coating the interior surface with a
hydrophobic composition, for instance by siliconisation. Siliconisation is
achieved by
processes that are well known to those skilled in the art. Alternatively, the
water
5 repellent interior surface is achieved by the container being made of a
water repellent
composition.
The presence of a water repellent interior surface of the container makes foam
formation more likely to occur and more reproducible. This allows lower polyol
10 concentrations to be used in the preservation sample which in turn
decreases the
length of time necessary to dry the sample, reduces the effect of Maillard
reactions or
other harmful interactions between the polyol and the active agent. Where the
preservation samples comprises a vaccine, the resultant solid is reconstituted
quickly
due to the lower amount of polyol present and the resultant vaccine solution
is less
15 viscous, allowing easier administration.
Dr yiing without freezing or foam formation
A particularly preferred method of the invention involves drying IPV in the
presence
20 of a stabilising agent, and preferably a bacterial polysaccharide, using a
gentle process
that avoids exposure of IPV to freezing or foam formation so that IPV is
subjected to
less stress during the drying process and a high degree of antigenicity is
retained.
This method is particularly applicable for use where a lower concentrationof
the glass
25 forming polyol, for example at concentration below 10% (w/v), more
preferably
below 5% (w/v), is advantageous and a shorter drying time is preferred.
Loss of solvent by evaporation (evaporative drying step b)
30 The process of drying without freezing or foam formation involves
subjecting the
preservation sample to such pressure and temperature conditions so that the
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
31
preservation sample looses solvent by evaporation, without the sample freezing
or
bubbling to form a foam.
The temperature within the preservation sample will, at times, be different
from that
external to the sample due to the endothermic nature of the evaporation
process.
References to temperature are to the conditions external to the preservation
sample,
for instance, where a large industrial freeze dryer is used, to the
temperature of the
shelf. This usually corresponds to the freeze dryer temperature setting.
Optionally a preliminary step of degassing the preservation sample is present
in the
method of the invention. The pressure is reduced to at or below 200mBars,
preferably
between 200 and 35mBars, for a period of at least 5 minutes before the
pressure is
reduced further.
A preferred embodiment of the invention achieves evaporative drying by
reducing the
pressure while controlling the temperature conditions. The pressure is
adjusted to at or
below 30, 25, 20, preferablyl5, 12, most preferably 10, 8 , 7, 6, 5, 4, 3, 2
or 1 mbar,
while maintaining the temperature setting at a temperature above 0 C,
preferably of
between 4 C to 37 C , 4 C to 10 'C, 10 C to 15 C; 15 C to 20 C; 20 C
to
25 C; 25 C to 30 C; or 30 C to 37 C; or 37 C to 45 C. These conditions
are
maintained for at least 1, 2, 3, 4, 5, 8, 10, 12, 16 or 24 hours, preferably
for between
2-4 hours, 4-6 hours, 6-8 hours, 8-12 hours or 12-18 hours. In a particularly
preferred
embodiment, the pressure is maintained above 2mbars where the temperature
setting
is 15 C in order to prevent freezing of the sample. In a preferred
embodiment, the
temperature is maintained at 15 C and the pressure is set to between 5-10
mBars,
more preferably 6-9m-Bars, most preferably around 8 mBars. Where a higher
temperature setting is used, slightly lower pressure is possible without
freezing the
sample and where a lower temperature setting is used, the pressure should be
maintained at the higher level to prevent freezing. Preferably the conditions
are
maintained for a sufficient period of time so that the evaporation rate has
slowed so
that the temperature of the sample is approximately the same as that external
to the
sample.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
32
Preferably, the preservation sample should not freeze or boil to form a foam
and
looses solvent to form a viscous liquid or a highly viscous liquid.
Removing solvent to form a highly viscous liquid
A subsequent stage of the method of the invention involves removing solvent
until the
preservation sample dries to form a highly viscous liquid without foam
formation and
preferably without freezing.
In one embodiment of the invention, this is achieved by maintaining the
pressure and
temperature conditions at those applied in the first evaporative drying stage.
For
instance, the pressure is maintained at or below at or below 30, 25, 20,
preferablyl 5,
12, most preferably 10, 8, 7, 6, 5, 4, 3, 2 or 1 mbar, while maintaining the
temperature setting at a temperature above 0 C, preferably of between 5 C to
37 -C, 5 C to 10 -C, 10 C to 15 C; 15 C to 20 C; 20 C to 25 C; 25 C to
30 C; or 30 C to 37 C. For a temperature setting of 15 C , a pressure of 5-
10mBars, preferably 6-9mBars, most preferably around 8mBars is maintained for
between 4-24 hours, preferably 1-4, 4-8, 8-12 or 12-16 hours. These
temperature and
pressure conditions are maintained for 1, 2, 3, 4, 5, 6, 8, 10, 12, 18 hours
or more in
order to obtain a highly viscous liquid with a solvent content less than or
equal to 15,
12, preferably 10, 8, 5, 4, 3, 2 or 1 % (w/w).
Another embodiment of the invention increases the temperature setting during
solvent
removal to a higher temperature setting than that maintained earlier in the
process.
This allows the solvent to leave the sample at a quicker rate so that the
method of the
invention can be completed in a shorter time. For instance, the temperature
setting is
increased to above 0 C, more preferably above 20 C, preferably between 5 C
and
37 'C, 5 C and 10 'C, 10 C and 20 C; 20 C and 30 C; more preferably 30 C
and 40 C; more preferably 40 C and 50 C; most preferably 50 C and 60 C
while
maintaining the pressure at or below 30, 25, 20, preferably 15, 12, most
preferably 10,
8 , 7, 6, 5, 4, 3, 2 or 1 mbar. These temperature and pressure conditions are
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
33
maintained for 1, 2, 3, 4, 5, 6, 8, 10, 12, 18 hours or more in order to
obtain a solid
with less than or equal to 15, 12, preferably 10, 8, 5, 4, 3, 2 or 1%. This
embodiment
requires the active agent to be heat stable at the temperature used for the
method to be
carried out successfully.
A preferred embodiment of the invention reduces the pressure setting during
solvent
removal (step c) to a lower pressure setting than that used earlier in the
process (step
b). This allows the solvent to leave the sample at a quicker rate so that the
method of
the invention can be completed in a shorter time. It also enables a higher
proportion of
the solvent to be lost. For instance, the pressure setting is set to at or
below 7, 6,
preferably 5, 4, 3, more preferably 2, 1.5, 1, most preferably 0.8, 0.5, 0.2,
0.1 , 0.05 ,
0.02, 0.01, or 0.005mbar, while maintaining the temperature at or above 0 C,
preferably between 10 C and 20 C; 20 C and 30 C; 30 C and 35 C or above
40 C. These temperature and pressure conditions are maintained for 1, 2, 3,
4, 5, 6, 8,
10, 12 or 18 hours or more in order to obtain a solid with a solvent content
less than or
equal to 15, 12, preferably 10, 8, 5, 4, 3, 2 or 1% (w/w) preferably as
determined by
Karl Fischer coulometric moisture analyser (Eur. J. Pharm. Biopharm. (2000)
50;
277-284).
Preferably, steps b) and c) should be completed in a time equal to or less
than 18
hours, more preferably 16, 14, 12, most preferably 10, 8, 6 or 4 hours.
A dried composition is a composition from which solvent has been removed by
evaporation, boiling, or sublimation leaving a solvent content less than or
equal to 15,
12, 10, more preferably 8, 5, 4, 3, 2 or 1 % (w/w) , preferably as determined
by the
Karl Fischer method. Preferred ranges of solvent content are 1-3%, 3-5%, 5-10%
or
10-15% (w/w). The term includes highly viscous liquids as well as dried foamed
glass
and lyophilised solids.
A highly viscous liquid is defined as a material from which solvent has been
removed
by evaporation without boiling, leaving a solvent content less than or equal
to 15, 12,
10, preferably 8, 5, 4, 3, 2 or 1 % (w/w) , preferably as determined by the
Karl Fischer
CA 02503871 2011-06-29
WO 2004/039399 PCT/EP2003/012160
34
method. Preferred ranges of solvent content are 1-3%, 3-5%, 5-10% or 10-15%
(w/w).
The highly viscous liquid has a sufficiently low solvent content such that the
active
agent is preserved in a stable state for at least 3,6, 9,12 or 24 months at 4
C, allowing
the active agent to retain at least 40, 50, 60, preferably 70, 80, 90 or 95%
of its
activity and/or antigenicity over this period. Preferably, the highly viscous
liquid has
a solid appearance but is a glass and is able to flow very slowly over a
period of 2, 4,
or 6 days, more preferably 1, 2, 3, 4, 6, 7, 10 or 12 months. The extremely
slow flow
may be measured by inverting a receptacle containing the highly viscous liquid
and
leaving at room temperature until the highly viscous liquid is observed to
flow. In a
preferred embodiment, the highly viscous liquid will not appear to flow after
2, 4 or 6
days, preferably 2, 3 or 4 weeks, more preferably 2, 4, 6, 8, 10 or 12 months
in an
inverted position.
A viscous liquid is defined as the product of the primary phase of solvent
removal, at
the end of which the majority of solvent has been lost from the sample. This
point can
be recognised because the rate of evaporation slows down so that the
temperature of
the sample returns to the ambient temperature as the endothermic effect of
bulk
evaporation is lost.
A foamed glass is a dried composition containing a glass forming polyol, which
is
formed by a method wherein the preservation sample is subjected to such
temperature
and pressure conditions that the sample bubbles vigorously or boils so that a
foam is
formed as the sample dries.
CA 02503871 2011-06-29
WO 2004/039399 PCT/EP2003/012160
Examples
The examples below are carried our using standard techniques, which are well
known
and routine to those of skill in the art, except where otherwise described in
detail. The
5 examples are illustrative, but do not limit the invention.
Example 1. Evaporative freezing process
*
The process was carried out using a Heto Drywinner 8-85 freeze-dryer in which
shelf
10 temperature may be regulated to within 1 C , the final temperature of the
condenser
is -85 C , pressure is regulated with a bleed valve and 6 thermocouples are
available
to measure the product temperature.
A preservation sample was made by adding a stabilising agent (either 10%
trehalose
15 or 3.5% sucrose) and an active agent to an aqueous solution. Samples were
put into
the freeze dryer with a shelf temperature maintained at a fixed temperature
setting of
15 C throughout the process. The pressure was initially reduced to 200mBar
and
maintained at this level for 10 minutes before reducing the pressure further.
At
1.5mBar, the solutions began to freeze due to evaporative cooling as shown in
figure
20 1. The pressure is further reduced to 0.1mBar to allow the samples to
become fully
frozen. The pressure was then increased to between 0.8mBar and 3.5mBar at
which
point a foam formed as water was lost from the sample. Under the conditions of
the
experiment, no boiling was seen in a control sample containing only water. The
samples may be loosing water through evaporation rather than through boiling.
After
25 18 hours under these conditions, the samples are dried and the foamed
solution
becomes a foamed glass.
A similar process was successfully performed keeping the shelf temperature at
other
temperature settings up to 37 C.
*Trade-mark
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
36
Example 2. Establishment of freezing conditions
Samples were made by dissolving sucrose in water to give 1%, 5%, 10% and 20%
solutions. Samples were put into the freeze dryer with a shelf temperature
maintained
at 15 C throughout the process. The pressure was initially reduced to 200mBar
and
maintained at this level for 10 minutes before reducing the pressure further
to
50mBars, SmBars, 2.5mBars, 0.75mBars, 0.4mBars and 0.2mBars. Each pressure
level was maintained for 20 minutes to allow the temperature to equilibrate
and the
temperature of the sample was read using a thermocouple. Thermocouples were
attached to samples with different sucrose concentrations and the temperatures
recorded in table 1 are mean values of the temperatures.
Results
All samples froze between 1.66 and 1.11mbars, irrespective of the
concentration of
sucrose present. The temperatures measured at different pressures were very
close to
those predicted from the triple point curve. Therefore the presence of sucrose
does not
appear to have a large effect on the temperature of the samples at different
pressures.
In a preferred method of the invention, it is necessary to avoid freezing of
the sample.
This could be achieved by maintaining the pressure above 2mBars using a shelf
temperature of 15 C. At lower temperatures the pressure should be maintained
at a
higher level whereas use of a higher temperature would allow the pressure to
be
reduced further without the samples freezing.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
37
Table 1
Pressure Measured temperature Theoretical temperature Liquid/frozen
1000mBar 15 C liquid
50mBar 15 C liquid
5mBar 1 C 1 C liquid
2.5mBar -5 C -7 C liquid
0.75mBar -21 C -21 C frozen
0.4mBar -22 C -27 C frozen
0.2mBar -27 C -32 C frozen
Example 3. Foaming conditions for samples with different sugar concentrations
Preservation samples containing 0%, 5%, 10%, 15%, 20%, 25% and 50% sucrose
were made. Samples were put into the freeze dryer with a shelf temperature
maintained at 15 C throughout the process. The pressure was initially reduced
to
200mbars and maintained at this level for 10 minutes before reducing the
pressure
further. The pressure was further reduced to 0.lmbars to allow the samples to
become
fully frozen. The pressure was then increased to either 0.788mbars, 0.812mbars
or
3.5mbars in subsequent experiment These conditions were maintained for 3 hours
for
the 3.5mbars and 0.812mbars experiments and for 6 hours for the 0.788 mbars
experiment. The physical characteristics of each sample were evaluated.
Results
As shown in table 2, at a pressure of 3.5mbars, a high sucrose concentration
of 50%
was required for reliable formation of foam. In contrast, a lower pressure of
0.8mbars
allowed reliable foam formation at lower sucrose concentrations of 10-25%. The
use
of lower sucrose concentration could be advantageous for preserved samples to
be
used in vaccines for instance. Therefore a process using 0.8mbars and a 10-25%
sucrose content is preferred.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
38
Table 2
Pressure %sucrose Physical characteristics
3.5mbars 20 4/5 foamed, 1/5 viscous liquid
3.5mbars 25 2/5 foamed, 3/5 viscous liquid
3.5mbars 50 5/5 foamed
0.812mbars 5 Ring of crystallisation and bubbles
0.812mbars 10 All foamed
0.812mbars 15 All foamed
0.812mbars 20 All foamed
0.812mbars 25 All foamed
0.788mbars 5 Ring of crystallisation and bubbles
0.788mbars 20 All foamed
0.788mbars 25 All foamed
0.788mbars 50 Foam and syrup
Example 4. The effect of using siliconized containers
Preservation samples containing 5%, 10%, 15% and 25% sucrose were made and
added to vials, some of which were siliconized. In one experiment, samples
were put
into the freeze dryer with a shelf temperature maintained at 15 C throughout
the
process. The pressure was initially reduced to 200mbars and maintained at this
level
for 10 minutes before reducing the pressure further. The pressure was further
reduced
to 2.8mbars for 3 hours. During this period, the pressure fell to 2.00mbars as
the
presence of water vapour decreased. The physical characteristics of each
sample were
evaluated.
In a second experiment, samples were put into the freeze dryer with a shelf
temperature maintained at 37 C throughout the process. The pressure was
initially
reduced to 200mbars and maintained at this level for 10 minutes before
reducing the
pressure further. The pressure was further reduced to 2.4mbars for 3 hours.
During
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
39
this period, the pressure fell to 1.06mbars as the presence of water vapour
decreased.
The physical characteristics of each sample were evaluated.
Results
Siliconization had an effect on the degassing of the samples. The reduction of
pressure to 200mbars resulted in degassing of samples in siliconized vials but
not in
unsiliconized vials. Degassing was seen by bubbling of the sample.
The siliconisation of the vial also made foam formation more likely to occur
and more
reproducible (table 3). Siliconisation of vials allows foam formation to occur
reproducibly at lower polyol concentrations. The lower polyol concentration
decreases the length of time necessary to dry the sample and reduces the
effect of
Maillard reactions or other interactions with the polyol harming the active
agent.
Where the sample involved is a vaccine, this reduces the viscosity of the
sample and
allows easier administration.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
Table 3
Temperature and % sucrose Characteristics Characteristics
pressure nonsiliconised vial siliconised vial
15 C, 2.8mbars 5% Viscous fluid
15 C, 2.8mbars 10% Viscous fluid foamed
15 C, 2.8mbars 15% Viscous fluid
15 C, 2.8mbars 25% Viscous fluid
37 C, 2.4mbars 5% 3 viscous fluid
2 foamed
37 C, 2.4mbars 10% All viscous fluid 5 foamed
1 viscous fluid
37 C, 2.4mbars 15% All foamed
37 C, 2.4mbars 25% All foamed
Example 5. Comparison of preservation of Hib-IPV by conventional freeze
5 drying or by foam drying
The active agent to be preserved was a mixture of the PRP polysaccharide of
Haemophilus influenzae b (Hib) and three strains of inactivated polio virus
(IPV). The
preservation sample was made by dissolving Hib-IPV in either a 3.15% sucrose
10 solution or a 10% trehalose solution.
The samples were lyophilised either by using a conventional freeze drying
sample that
required three days to perform in a large freeze dryer, or by using the foam
drying
method described in example 1.
The samples were reconstituted in water and an ELISA was used to assess the
retention of antigenicity of the three polio virus strains. Three polyclonal
antibodies
and three monoclonals, one against each strain, were used in separate ELISAs.
Results are presented as a percentage of the reading given for a sample which
had not
undergone the freeze drying or foam drying procedure.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
41
The preserved samples are assessed for their immunogenicity in vivo by
inoculating
groups of ten mice with the reconstituted IPV-Hib, withdrawing blood from the
mice
and monitoring levels of antibodies against IPV and Hib polysaccharides, for
instance
by ELISA or Western blotting. The degree of protection is assessed in a
challenge
mouse model.
Results
Using either sucrose or trehalose as the polyol, the antigenicity of IPV was
maintained
better using the foam drying technique compared to using conventional freeze
drying.
Table 4
Method of drying Polyol content ELISA - type 1/2/3 %
Polyclonal Monoclonal
Freeze drying 3.15% sucrose 46/49/58* 25/0/0
Foam drying 3.15% sucrose 85/97/106 55/68/57
Freeze drying 10% trehalose 47/43/58
Foam drying 10% trehalose 93/86/84 72/75/87
* The experiment freeze drying in the presence of 3.15% sucrose was repeated
five
times and the results shown are from one representative experiment.
Example 6. Protective effect of freeze drying IPV in the presence of Hib
polysaccharides.
Preservation samples were prepared containing 3.15% sucrose and IPV or a
mixture
of IPV and Hib polysaccharides. The samples were inserted into a Heto
Drywinner 8-
85 freeze-dryer and freeze dried at a temperature setting of -32 C for 40
hours
followed by continued drying at 4 C for 16 hours.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
42
The samples were reconstituted in water and an ELISA was used to assess the
retention of antigenicity of the three polio virus strains. Three monoclonal
antibodies,
one against each strain, were used in separate ELISAs to assess the degree of
antigen
retention in the reconstituted, freeze dried sample compared to a reference
sample that
had not been frozen. Results are presented as a percentage of the reading
given for a
sample which had not undergone the freeze drying or foam drying procedure.
Results
As shown in table 5, the presence of Hib polysaccharide in the preservation
sample
with IPV, led to greater retention of IPV antigens after freeze drying than
that
achieved when IPV was freeze dried alone. The Hib polysaccharides have a
preserving effect on IPV antigenicity in addition to that achieved by having
sucrose
present as a stabilising agent.
Table 5
Composition freeze dried Polyol content ELISA - type 1/2/3 %
IPV 3.15% sucrose 26/25/0
IPV-Hib 3.15% sucrose 52/68/0
Example 7. Effect of different stabilising agents on freeze drying IPV-Hib
Preservations samples were made containing IPV-Hib and using either 3.15%
sucrose; 2.5% sorbitol, 0.8% glutamine and 0.01% HSA; MMR stabiliser and
lactose;
3% glycine, 2% arginine and 4% sucrose; or 4% sucrose and 2% glycine as
stabilising
agent. The experiment included a sample with 3.15% sucrose as stabilising
agent
using double the concentration of IPV-Hib. The samples were freeze dried using
a
conventional three day freeze drying cycle in a batch freeze dryer.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
43
The samples were reconstituted in water and an ELISA was used to assess the
retention of antigenicity of the three polio virus strains. Three polyclonal
antibodies
and three monoclonals, one against each strain, were used in separate ELISAs.
Results are presented as a percentage of the reading given for a sample which
had not
undergone the freeze drying or foam drying procedure.
The preserved samples are assessed for their immunogenicity in vivo by
inoculating
groups of ten mice with the reconstituted IPV-Hib, withdrawing blood from the
mice
and monitoring levels of antibodies against IPV and Hib polysaccharides, for
instance
by ELISA or Western blotting. The degree of protection is assessed in a
challenge
mouse model.
Results
Increasing the dose of IPV from 40/8/32 DU/dose to 80/16/64 DU/dose led to an
increase in retention of antigenicity of IPV as shown in table 6. Variation in
the
stabilising agent also influenced retention of antigens with 4% sucrose/2%
glycine
and 2.5% sorbitol/0.8% glutamine/0.01% HAS producing higher retention of
antigens
as shown by ELISA data.
Table 6
Stabilising agent Polyclonal ELISA results Monoclonal ELISA results
3.15% sucrose 50/50/70 25/0/0
2.5% sorbitol 55/72/72 33/50/0
0.8% glutamine
0.01% HSA
MMR stabiliser 59/62/65 28/25/0
lactose
3.15% sucrose 84/92/120 102/138/0
Double dose of IPV-Hib
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
44
3% glycine
2% arginine
4% sucrose
4% sucrose 46/62/78 25/50/15
2% glycine
Example 8. Reproducibility of sample quality after freeze drying, foam drying
or foam drying with a freezing step.
Preservation samples are made up comprising IPV, mumps, measles, rubella,
varicella
zoster virus, CMV, hepatitis, HSV1, HSV2, respiratory syncitial virus, dengue,
paramyxoviridae such as parainfluenza, togaviridae and influenza viruses,
and/or Hib
as the active agent. The active agent is dissolved in an aqueous solution
containing a
polyol. Multiple samples are preserved by either freeze drying, foam drying
using a
freezing step following the protocol described in example 1, or foam drying
without a
freezing step using a protocol described in example 4. Samples are
reconstituted in an
aqueous solution and their activity assessed. This is accomplished using ELISA
assays as described in example 5 using antibodies specific to native antigens.
In the
case of live viruses, the titre of each sample is established by using the
virus to infect
suitable host cells and assessing the infectivity by plaque formation or by
immunocytochemistry. Where immunogenic compositions or vaccines are foam
dried,
the retention of immunogenicity can be tested in an animal model by immunising
groups of animals with vaccine which is foam dried or freeze dried and
boosting the
immune response for instance at 14 and 28 days after the first immunisation.
Serum is
isolated from animals at the end of the immunisation schedule and its titre
against the
vaccine is tested using standard assays, for instance by ELISA,
immunocytochemistry, Western blotting, immunoprecipitation, serum
bacteriocidal
assay or agglutination assay. Results are complied, first by comparing the
activity of
the active agent after freeze drying, foam drying with a freezing step, or
foam drying
without a freezing step. Secondly, the degree of reproducibility of the
preservation
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
technique is assessed by comparing the range of activities after subjecting
samples to
each of the three preservation methods.
Example 9. Long term storage of active agents preserved by freeze drying, and
5 foam drying.
Preservation samples are made up comprising IPV, mumps, measles, rubella,
varicella
zoster virus, CMV, hepatitis, HSV1, HSV2, respiratory syncitial virus, dengue,
parainyxoviridae such as parainfluenza, togaviridae and influenza viruses,
and/or Hib
10 as the active agent. The active agent is dissolved in an aqueous solution
containing a
polyol. Multiple samples are preserved by either freeze drying, foam drying
using a
freezing step following the protocol described in example 1, or foam drying
without a
freezing step using a protocol described in example 4. Samples are aged by
storing at
37 C or 23 C for seven days and are compared for activity with samples that
have
15 been keep at 4 C . Samples are reconstituted in an aqueous solution and
their activity
assessed. This will be accomplished using ELISA assays as described in example
5
using antibodies specific to native antigens. In the case of live viruses, the
titre of
each sample is established by using the virus to infect suitable host cells
and assessing
the infectivity by plaque formation or by immunocytochemistry. Results are
20 complied, first by comparing the activity of the active agent after storage
at elevated
temperatures with storage at 4 C. Secondly, the degree of reproducibility of
the
preservation technique is assessed by comparing the range of activities after
subjecting samples to each set of conditions.
25 Example 10. Method for drying without freezing or foam formation
Preservation samples containing 5%, 10%, 15% and 25% sucrose were made and
added to vials. Samples were put into a freeze dryer at a temperature setting
of 15 C
throughout the process. The pressure was initially reduced to 200mBars and
30 maintained at this level for 10 minutes to allow degassing before reducing
the
pressure further. The pressure was further reduced to 8mbars for two to three
hours
during which time thermocouples inside the samples showed that the sample
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
46
temperature reduced to 4 C due to evaporative cooling. After 2-3 hours, the
temperature of the samples returned to 15 C, indicating that evaporation
under these
temperature and pressure conditions was near completion. During this stage of
the
process, the sample did not boil to form a foam or freeze so that an active
agent within
the sample is exposed to as little stress as possible. The samples have a
solid
appearance, similar to the final product.
Further drying of the samples was achieved by reducing the pressure further to
0.lmbars while keeping the shelf temperature setting at 15 C. These
conditions were
maintained for a further 10-16 hours. During this phase, the sample
temperature
remained at 15 C since the rate of evaporation was slow. Further drying took
place
and the resultant sample had a solid appearance. If the sample was place on
its side,
the sample contents slowed very slowly, over a period of days or months
showing that
the sample is a liquid glass of high viscosity. Figure 2 shows that the
containing
holding the highly viscous liquid can be inverted without provoking immediate
flow
of the highly viscous liquid.
Example 11 Retention of IPV immunogenicity after drying without freezing or
foam formation
Samples dried according to the method of example 10 have not been subjected to
stresses associated with the bubbling that accompanies foam formation or
freezing.
Experiments were performed to determine whether this method produced a high
level
of antigen retention when used to dry 1PV.
Three separate experiments were performed in which IPV was resuspended in an
aqueous solution with 10% sucrose or 10% trehalose as the stabilising agent.
The
samples were put into siliconised vials which were placed into a Heto
Drywinner 8-85
freeze-dryer and the temperature was set to 15 C. The pressure was initially
reduced
to 35mBars to degas the sample. After 10 minutes, the pressure was further
reduced to
8mBars and was kept at this level for two hours. During this period the
temperature
setting was kept at 15 C and the temperature into the sample was monitored.
As
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
47
water evaporated from the sample, the temperature dropped to 4 C but towards
the
end of the two hours, the temperature returned to 15 C as the rate of
evaporation
slowed. No bubbling or foam formation occurred under these conditions. The
pressure
was then reduced further to 0.lmbars and these conditions were maintained for
16
hours more in the first two experiments and for 10 hours more in the third
experiment.
The samples were reconstituted in water and an ELISA was used to assess the
retention of antigenicity of the three polio virus strains. The monoclonal
antibody
against type 3 IPV, was used in an ELISA to assess the degree of antigen
retention in
the reconstituted, freeze dried sample compared to a reference sample that had
not
been frozen. Results are presented as a percentage of the reading given for a
sample
which had not undergone a drying procedure.
Results
The dried samples had a solid appearance however they appeared to be in the
form of
a highly viscous liquid/glass since, over a period of days, the dried solid
was able to
flow if the container was inverted at room temperature.
Table 7 Retention of type 3 IPV antigen as determined by ELISA using a
monoclonal
antibody (drying without foaming or freezing)
Formulation 1St experiment 2" experiment 3r experiment
(18 hour cycle) (18 hour cycle) (12 hour cycle)
10% sucrose 75% 78% 91%
10% trehalose 82% 79% 93%
These levels of type 3 IPV antigen retention compares very favourably with the
freeze
drying results shown below where very low values were usually found in the
same
ELISA format when a monoclonal antibody against type 3 was used.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
48
Table 8: Retention of type 1, 2 and 3 IPV antigens as determined by ELISA
using a
monoclonal and polyclonal antibodies (freeze drying)
Method of drying Polyol content ELISA - type 1/2/3 %
Polyclonal Monoclonal
Freeze drying 3.15% sucrose 46/49/58* 19/25/0
Freeze drying 10% trehalose 47/43/58 25/0/0
* The experiment freeze drying in the presence of 3.15% sucrose was repeated
five
times and the results shown are from one representative experiment.
Example 12 Long term storage stability of dried IPV stored as a highly viscous
liquid/glass.
IPV dried using the method described in Example 11 was stored at 4 C for 9
months.
The samples were reconstituted in water with 150mM NaCl and an ELISA was used
to assess the retention of antigenicity of the three polio virus strains.
Three
monoclonal antibodies, one against each strain, were used in separate ELISAs
to
assess the degree of antigen retention in the reconstituted stored sample. A
similar
ELISA had been carried out on reconstituted samples from the same batch prior
to
storage. All results were compared to a reference sample that had not been
dried.
Results are presented as a percentage of the reading given for a sample which
had not
undergone a drying procedure.
Results
Table 9. Retention of IPV antigens after storage as a highly viscous liquid
for 9
months
Treatment Type 1 ELISA Type 2 ELISA Type 3 ELISA
Dried/reconstituted 72% 75% 88%
Not stored
Dried/reconstituted 70% 94% 90%
9 months 4 C
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
49
Therefore IPV which has been dried by the method described in Example 11 can
be
stored at 4 C for at least 9 months without loss of antigenicity.
Example 13 Comparison of the immunogenicity in vivo of IPV after drying to
form a highly viscous liquid and reconstitution compared to undried IPV
Groups of 10 Wistar rats were inoculated with various dilutions of IPV which
had
been dried in the presence of 10% sucrose to form a highly viscous liquid
using the
method disclosed in Example 10 and reconstituted. Further groups of 10 Wistar
rats
were inoculated with reference samples of IPV which had been prepared in the
same
way but which had not been dried.
After 21 days, sera were taken from all the rats and the sera were tested in
separate
immunoprecipitation assays using Type 1, Type 2 and Type 3 polio virus.
Results are shown in table 10 that contains:- a) the number of responant rats
for each
IPV dilution, b) the ED50 which is the dose that is required to ensure that
50% of the
rats seroconvert as assessed by the immunoprecipitation assay and c) the
relative
potency of the dried and reconstituted IPV compared to the undried reference
IPV.
Table 10. Immuno eg nicity of IPV after drying to form a high viscosity liquid
(JLEO17/05) and reconstitution compared to an undried reference IPV (JLE097)
Sample Number of respondant ED50 RP relative
undiluted 1/1.25 1/3.125 1/7.81 potency
JLEO 17/05
Type 1 10 9 6 5 6.37 0.956
Type 2 6 4 3 3 7.14 0.825
Type 3 6 8 2 1 18.18 1.051
JLE097
Type 1 10 10 10 7 3.33 1.120
Type 2 8 6 5 2 3.12 0.951
Type 3 7 6 4 1 16.91 1.172
Reference
Type 1 10 8 4 6.37
Type 2 7 5 2 2.93
Type 3 5 3 0 22.57
JLEO17/05 is a IPV batch that was dried to form a highly viscous liquid and
subsequently reconstituted. JLE097 is the undried reference.
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
Table 10 shows that the number of respondants inoculated with each dilution of
IPV
is similar between the two batches of dried and reconstituted IPV and the
undried
reference sample. In general, Type 1 IPV elicited the best immune response,
with
Type 2 eliciting an immune response in slightly fewer rats. Type 3 elicited
the
5 weakest immune response.
The process of drying to form a highly viscous liquid does not impair the
ability of
IPV to elicit immunoprecipitating antibodies in vivo. A relative potency (RP)
reading
of 1.0 indicates that the sample elicits an equivalent response to the
reference sample.
10 Both dried samples produce RP readings of close to 1.0 for all three types
of polio
virus indicating the drying process does not effect the ability of the sample
to elicit an
immune response.
Example 14 Effect of drying to form a highly viscose liquid using sucrose or
15 trehalose as stabilising agent on the ability of IPV to elicit an
immunoprecipitating immune response in vivo
Groups of 10 Wistar rats were inoculated with IPV which had been dried in the
presence of either 10% sucrose or 10% trehalose as described in Example 2, and
then
20 reconstituted. Further groups of 10 Wistar rats were inoculated with an
equivalent
amount of IPV that had not been dried, as reference samples.
After 21 days, sera were collected from all rats and an immunoneutralisation
assay, as
described in Example 5 was used to assess the amount of immunoneutralising
25 antibody that had been raised against each of Type 1,Type 2 and Type 3
polio virus.
Relative potencies were calculated for each sample by comparing the immune
response to that elicited by the undried reference sample.
30 Results are shown in Table 11.
Table 11. Comparison of drying in sucrose and trehalose
Lot Number Sugar present Relative potency in vivo Humidity % Duration
Type 1/ Type 2/ Type3 Karl Fischer (hours)
J1e017 10% trehalose 0.95 / 0.82 / 1.05 nd 7
31 C03/01 10% sucrose 0.69 / 1.20 / 0.97 4.6% 18
31C03/02 10% trehalose 0.60 / 0.94 / 0.9 11.5% 18
03D02/01 10% sucrose 0.74 / 1.05 / 0.96 5.9% 12
03D02/02 10% trehalose 0.58 / 0.98 / 1.06 10.6% 12
The amount of water remaining in samples was lower when sucrose was used as
stabilising agent with approximately 5% humidity remaining compared to
CA 02503871 2005-04-27
WO 2004/039399 PCT/EP2003/012160
51
approximately 10% when trehalose was used as the stabilising agent measured by
the
Karl Fischer method.
Both sucrose and trehalose were effective at stabilising IPV during the drying
process
so that the reconstituted IPV gave relative potency readings approaching 1.0
for most
of the different types of polio virus. The relative potencies were
particularly good for
Type 3 polio virus which looses its immunogenicity relatively easily.
Example 15: Measurement of humidity by Karl Fischer
Analysis was carried out in a Karl Fischer titrometer (Aqua 30.00 -
Elektrochemie
Halle). The sample was weighed out and placed into the oven at a setting of 80
C.
The sample was flushed with nitrogen gas and then added to hydranal reagent
(Riedel
de Hahn) in order to perform the analysis by coulometry.
